Elucidation of the cancer progression through the a5b3 integrin pathway for establishment of a noval treatment for tumor growth

• Project/Area Number: 15K20502
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Surgical dentistry
• Research Institution: Chiba University
• Principal Investigator: MINAKAWA YASUYUKI 千葉大学, 大学院医学研究院, 特任助教 (30639787)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000); Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: α5β3integrin / Angiopietin-like3 / 口腔扁平上皮癌 / α5β3インテグリン / Angiopoietin-like 3

Outline of Final Research Achievements

Significant ANGPTL3 up-regulations were found in oral squamous cell carcinoma (OSCC) cell lines and primary OSCC patients compared with normal counterparts. Using ANGPTL3 knockdown cells, we revealed that decreased tumoral growth was closely correlated with cell-cycle arrest at the G1 phase via MAPK signaling cascades. In addition, ANGPL3 controlled α5β3 integrins in OSCCs, indicating that ANGPTL3 may play an important role in OSCC progression and diagnostic/therapeutic targets for the patients with OSCC.

Research Products

• [Journal Article] ANGPTL3 is a novel biomarker as it activates ERK/MAPK pathway in oral cancer. (2015)
  • Author(s): Koyama T, Ogawara K, Kasamatsu A, Okamoto A, Kasama H, Minakawa Y, Shimada K, Yokoe H, Shiiba M, Tanzawa H, Uzawa K
  • Journal Title: Cancer Med. Volume: 4 Issue: 5 Pages: 759-69
  • DOI: 10.1002/cam4.418
  • Peer Reviewed